Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AERAS-404 in Healthy Adults
NCT02066428Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Nov 2007
- Primary completion
- May 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H4:IC31 in Tuberculosis (TB) (8 arms), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Safety of one or two injections of AERAS 404 at 182 days. Started Nov 2007; status: completed.
02
Drugs
H4:IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02066428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066428.